---
title: "Corvus Q2 FY26 net loss widens to $18 million; R&D expense more than doubles to $16 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295136743.md"
description: "Corvus Pharmaceuticals reported a widened Q2 FY26 GAAP net loss of $17.96 million, driven by R&D expenses more than doubling to $15.96 million due to increased clinical trial and personnel costs. The company's cash position rose to $215.23 million, extending its operating runway into Q2 2028. Enrollment remains on track for key Phase 3 and Phase 2 trials, with new soquelitinib studies in hidradenitis suppurativa and asthma expected later this year."
datetime: "2026-08-06T20:04:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295136743.md)
  - [en](https://longbridge.com/en/news/295136743.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295136743.md)
generator: "portal-rs"
---

# Corvus Q2 FY26 net loss widens to $18 million; R&D expense more than doubles to $16 million

-   Corvus Pharmaceuticals posted a GAAP net loss of $17.96 million, or $0.19 a share, for Q2 2026, widening from $8 million, or $0.10. \* R&D expense more than doubled to $15.96 million, due to higher soquelitinib clinical trial costs and higher personnel-related costs. \* Cash, cash equivalents and marketable securities rose to $215.23 million at June 30, extending expected operating runway into Q2 2028. \* Enrollment stayed on track in the registrational Phase 3 relapsed/refractory PTCL trial and the SIERRA1 Phase 2 atopic dermatitis study. \* Richard A. Miller said Corvus expects to start soquelitinib studies in hidradenitis suppurativa and asthma later this year. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corvus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061601PRIMZONEFULLFEED9805396) on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CRVS.US](https://longbridge.com/en/quote/CRVS.US.md)

## Related News & Research

- [Corvus publishes final Phase 1/1b soquelitinib data in Blood supporting Phase 3 relapsed/refractory PTCL trial](https://longbridge.com/en/news/297177476.md)
- [Corvus Pharmaceuticals (NASDAQ:CRVS) Posts Earnings Results, Misses Expectations By $0.03 EPS](https://longbridge.com/en/news/295291601.md)
- [Upstream Bio plans Q1 2027 start for Phase 3 verekitug trials in severe asthma, nasal polyps](https://longbridge.com/en/news/297641472.md)
- [Booz Allen Hamilton declares BRL 0.21 dividend per unit for Q3 2026](https://longbridge.com/en/news/297698785.md)
- [Universe Pharmaceuticals Sets September 30, 2026 AGM With Contingent Reverse Stock Split Proposal](https://longbridge.com/en/news/297704810.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**